Coverage of reforms in provider payment systems and hospital financing models that reshape utilization, access dynamics, and downstream commercial implications.
Nov 08, 2023
China's Medical Service Pricing Reform: 3 Core Challenges
China's medical service pricing reform is pivotal in reshaping China's healthcare landscape, impacting not only inpatient
Oct 25, 2023
Wonder Sir Founder on the State of Rare Disease Patient Organizations in China
This is the last part of my conversation with Wonder Sir founder Chen Yiwei. You can find our interview'
Sep 27, 2023
Wonder Sir Founder on Pharma Success: The Importance of Early Investment and Trust in China
“In my capacity as a researcher, I've had experience in both scientific research and drug development. Additionally, as
Aug 30, 2023
Improving Access to Innovative Drugs: Can China’s Dual-Channel Policy Deliver?
To tackle the hospital formulary access issues faced by some NRDL-negotiated drugs, the National Healthcare Security Administration (NHSA) introduced the
Jul 19, 2023
Chinese Organization for Rare Disorders Founder Kevin Huang: China is Focusing on Solving Orphan Drug Access Issues
On a beautiful Wednesday morning, just after celebrating July 4th, I sat down with Kevin Huang, the visionary founder of
Jul 05, 2023
Behind the Scenes: Exploring the Roadblocks to Formulary Listing for NRDL-Negotiated Drugs in China Public Hospitals
China's National Reimbursement Drug List (NRDL) is increasingly incorporating innovative drugs. Once included in the NRDL, these drugs
Jun 07, 2023
Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities
In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
May 10, 2023
How China’s Provider Payment Reform Will Impact Key Healthcare Stakeholders
Our last article discussed the context behind the DRG/DIP payment reform and how China has adopted this dual-track payment